Mayo and NCI researchers find that trastuzumab continues to show life for HER2-positve early stage breast cancer

After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer. …read more

Source: Cancer